Last updated: 11/03/2018 20:34:09
A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects with BRAF V600 Mutation Positive Tumors
Clinicaltrials.gov ID
EudraCT ID
EU CT Number
Not applicable
Trial status
Completed
Completed
Trial overview
Official title: An Open-label Study to Evaluate the Effects of a Potent CYP3A4 Inducer and the Effects of a pH Elevating Agent on the Repeat Dose Pharmacokinetics of Dabrafenib (GSK2118436) in Subjects with BRAF V600 Mutation Positive Tumors
Trial description: The study is being conducted to evaluate the effect of rifampin (a strong CYP3A4 inducer) and rabeprazole (a pH elevating agent) on the PK of dabrafenib (a CYP3A4/CYP2C8 substrate). The study will be conducted in subjects with BRAF V600 mutation-positive tumors. Data collected from this study will be used to inform recommendations regarding use of concomitant medications with dabrafenib and future clinical pharmacologic evaluation of dabrafenib.
Primary purpose:
Treatment
Trial design:
Single Group Assignment
Masking:
None (Open Label)
Allocation:
Non-randomized
Primary outcomes:
PK assessment (Cmax) of Dabrafenib with and without Rabeprazole or Rifampin
Timeframe: Day 15, 19 and Day 29
PK assessment (tmax) of Dabrafenib with and without Rabeprazole or Rifampin
Timeframe: Day 15, 19 and Day 29
PK assessment (AUC[0-tau]) of Dabrafenib with and without Rabeprazole or Rifampin
Timeframe: Day 15, 19 and Day 29
Secondary outcomes:
PK assessment of Dabrafenib co administered with rabeprazole or rifampin
Timeframe: Day 15, 19 and Day 29
PK assessment (AUC[0-tau]) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib
Timeframe: Day 15, 19 and Day 29
PK assessment (Cmax and Ctau,) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib
Timeframe: Day 15, 19 and Day 29
PK assessment (tmax) of hydroxy-dabrafenib, carboxy-dabrafenib, and desmethyl-dabrafenib
Timeframe: Day 15, 19 and Day 29
Ratio of metabolite to Dabrafenib
Timeframe: Day 15, 19 and Day 29
Safety and tolerability assessment to measure vital signs
Timeframe: Day 15, 19 and Day 29
Safety and tolerability assessment for 12-lead ECG
Timeframe: From Screening up to follow up visit within 7-10 days of the last dose of study medication
Safety and tolerability assessment for laboratory tests
Timeframe: From Screening up to follow up visit within 7-10 days of the last dose of study medication
Safety and tolerability assessment of dabrafenib in combination with rabeprazole or rifampin
Timeframe: From Screening up to follow up visit within 7-10 days of the last dose of study medication
Concentrations of Rabeprazole in the presence of Dabrafenib
Timeframe: Predose, 1, 2, 3 and 12 hours postdose on Day 19
Concentrations of Rifampin in the presence of Dabrafenib
Timeframe: Predose, 1, 2, 3 and 12 hours postdose on Day 29
Interventions:
Drug: Dabrafenib 150 mg twice a day (BID)
Drug: Rabeprazole 40 mg once daily (OD)
Drug: Rifampin 600 mg OD
Enrollment:
23
Observational study model:
Not applicable
Primary completion date:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Not applicable
Medical condition
Cancer
Product
dabrafenib
Collaborators
Not applicable
Study date(s)
December 2013 to February 2016
Type
Interventional
Phase
1
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
No
- Male or female at least 18 years of age at the time of signing the informed consent form.
- Provided signed written informed consent.
- History of another malignancy with exceptions below, or any malignancy with confirmed activating RAS mutation. Exception: (a) Subjects who have been successfully treated and are disease-free for 5 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission, or (e) indolent prostate cancer (definition: clinical stage T1 or T2a, Gleason score <=6, and PSA <10 nanogram per milliliter [ng/mL]) requiring no or only anti-hormonal therapy, are eligible.
- Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of dabrafenib.
Inclusion and exclusion criteria
Inclusion criteria:
- Male or female at least 18 years of age at the time of signing the informed consent form.
- Provided signed written informed consent.
- Capable of compliance with the requirements and restrictions listed in the consent form.
- Body weight >=45 kilogram (kg) and a body mass index (BMI) >=19 Kilogram per meter squared (kg/m^2) and <40 kg/m^2 (inclusive).
- Able to swallow and retain oral medication.
- BRAF V600 mutation-positive tumor as confirmed in a Clinical Laboratory Improvement Amendments (CLIA)-approved laboratory or equivalent.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Adequate baseline organ function defined in study protocol.
- Women of child-bearing potential must be willing to practice acceptable methods of birth control. Additionally, women of childbearing potential must have a negative serum pregnancy test within 14 days prior to the first dose of study medication.
Exclusion criteria:
- History of another malignancy with exceptions below, or any malignancy with confirmed activating RAS mutation. Exception: (a) Subjects who have been successfully treated and are disease-free for 5 years, (b) a history of completely resected non-melanoma skin cancer, (c) successfully treated in situ carcinoma, (d) CLL in stable remission, or (e) indolent prostate cancer (definition: clinical stage T1 or T2a, Gleason score <=6, and PSA <10 nanogram per milliliter [ng/mL]) requiring no or only anti-hormonal therapy, are eligible.
- Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last 3 weeks, or chemotherapy without delayed toxicity within the last 2 weeks, preceding the first dose of dabrafenib.
- Unresolved toxicity greater than Grade 2 from previous anti-cancer therapy except alopecia.
- Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with subject’s safety, obtaining informed consent or compliance to the study procedures.
- Current use of therapeutic warfarin.
- Any prohibited medication(s) or herbal preparation as described in study protocol or requires any of these medications during the study.
- Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to dabrafenib, rabeprazole and rifampin, or excipients that contraindicates their participation.
- Pregnant or nursing females.
- A history or evidence of cardiovascular risk including any of the following: a QT interval corrected for heart rate using the Bazett’s formula (QTcB) >=480 milliseconds (msec); a history or evidence of current clinically significant uncontrolled arrhythmias; a history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within 6 months prior to randomization; a history or evidence of current >=Class II congestive heart failure (CHF) as defined by the New York Heart Association (NYHA) guidelines; Abnormal cardiac valve morphology (>=grade 2) documented by echocardiogram (subjects with grade 1 abnormalities [i.e., mild regurgitation/stenosis] can be entered on study). Subjects with moderate valvular thickening should not be entered on study.
- Presence of active gastrointestinal (GI) disease or other condition (e.g., small bowel or large bowel resection) that will interfere significantly with the absorption of drugs. If clarification is needed as to whether a condition will significantly affect absorption of drugs, contact the GSK Medical Monitor.
- A history of known Human Immunodeficiency Virus (HIV), Hepatitis B Virus, or Hepatitis C Virus infection.
- Subjects with brain metastases are excluded if their brain metastases are: Symptomatic, Treated (surgery, radiation therapy) but not clinically and radiographically stable one month after local therapy, or asymptomatic and untreated but >1 centimeter (cm) in the longest dimension. Subjects with small (<=1 cm in the longest dimension), asymptomatic brain metastases that do not need immediate local therapy can be enrolled. Subjects on a stable dose of corticosteroids for >1 month, or those who have been off corticosteroids for at least 2 weeks can be enrolled. Subjects must also be off of enzyme-inducing anticonvulsants for more than 4 weeks.
Trial location(s)
Location
GSK Investigational Site
Goodyear, Arizona, United States, 85338
Status
Study Complete
Location
GSK Investigational Site
Tacoma, Washington, United States, 98405
Status
Study Complete
Location
GSK Investigational Site
Heidelberg, Victoria, Australia, 3084
Status
Terminated/Withdrawn
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Completed
Actual primary completion date
Not applicable
Actual study completion date
2016-29-02
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Participate in clinical trial
Additional information
Results for study 200072 can be found on the GSK Clinical Study Register.
Click hereAccess to clinical trial data by researchers
Visit website